ArticleMolecular cancer2023
Crosstalk between 5-methylcytosine and N
Open access · goldAbstract read
In one paragraph
Article in Molecular cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed
19.4field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 106 citations in OpenAlex.
- Coordinated DNA methyltransferase 3A and methyltransferase-like 7A activity reprograms the tumor microenvironment through discoidin domain receptor 1 signaling.Cancer biology & medicine · 2026Article
- METTL3-mediated mMolecular cancer · 2026Article
- M6AREG 2.0: the landscape of m6A-centered crosstalk with diverse epigenetic regulation.Nucleic acids research · 2026Article
- Review
- Advances in research on RNA methylation and its role in the immune microenvironment of gastrointestinal tumors.Frontiers in cell and developmental biology · 2026Review
- Recent advances in m6A RNA modification in hepatocellular carcinoma: from mechanisms to therapeutic potential.Frontiers in molecular biosciences · 2026Review
- TUBB1 promoter methylation is a promising biomarker for predicting HBeAg seroconversion in chronic hepatitis B.Microbiology spectrum · 2025Article
- KYNA Ameliorates Hepatic Ischemia-Reperfusion Injury by Activating the Hippo Signalling Pathway via FTO-Dependent m6A Demethylation of LATS1.Cell proliferation · 2025Article
- A Machine Learning Framework for Screening Plasma Cell-Associated Feature Genes to Estimate Osteoporosis Risk and Treatment Vulnerability.Biochemical genetics · 2025Article
- Article
- An Integration of RNA Sequencing and Network Pharmacology Approaches Predicts the Molecular Mechanisms of the Huo-Xue-Shen Formula in the Treatment of Liver Fibrosis.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Exploring the methyl-verse: Dynamic interplay of epigenome and m6A epitranscriptome.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Review
- hsa_circ_0008305 facilitates the malignant progression of hepatocellular carcinoma by regulating AKR1C3 expression and sponging miR-379-5p.Scientific reports · 2025Article
- Comprehensive Bioinformatic Analysis Reveals an Autophagy-related Gene Signature for Predicting Outcome, Immune Status, and Drug Sensitivity in Hepatocellular Carcinoma.Recent patents on anti-cancer drug discovery · 2025Article
- RCDdb: A manually curated database and analysis platform for regulated cell death.Computational and structural biotechnology journal · 2024Article
- Article
- MicroRNA-mediated autophagy and drug resistance in cancer: mechanisms and therapeutic strategies.Discover oncology · 2024Review
- DNA 5mC and RNA mInternational journal of molecular sciences · 2024Article
- Overexpression of ESYT3 improves radioimmune responses through activating cGAS-STING pathway in lung adenocarcinoma.Experimental hematology & oncology · 2024Article
- Examining the evidence for mutual modulation between m6A modification and circular RNAs: current knowledge and future prospects.Journal of experimental & clinical cancer research : CR · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 9 institutions in 1 country.
Yu Tian *Department of General Surgery and Integrated Chinese and Western Medicine, Institute of Precision Diagnosis and Treatment of Digestive System Tumors, Carson International Cancer Center, Shenzhen University General Hospital, Shenzhen University, Shenzhen, Guangdong, 518055, China.
Haijuan Xiao *Department of Oncology, Shaanxi Province, Affiliated Hospital of the Shaanxi University of Traditional Chinese Medicine, Xianyang, Shaanxi, 712046, China.
Yanhui Yang *Department of General Surgery and Integrated Chinese and Western Medicine, Institute of Precision Diagnosis and Treatment of Digestive System Tumors, Carson International Cancer Center, Shenzhen University General Hospital, Shenzhen University, Shenzhen, Guangdong, 518055, China.
Pingping Zhang *Department of Gastroenterology, Changhai Hospital, Naval Medical University, Shanghai, 200433, China.
Jiahui YuanDepartment of General Surgery and Integrated Chinese and Western Medicine, Institute of Precision Diagnosis and Treatment of Digestive System Tumors, Carson International Cancer Center, Shenzhen University General Hospital, Shenzhen University, Shenzhen, Guangdong, 518055, China.
Wei ZhangDepartment of General Surgery and Integrated Chinese and Western Medicine, Institute of Precision Diagnosis and Treatment of Digestive System Tumors, Carson International Cancer Center, Shenzhen University General Hospital, Shenzhen University, Shenzhen, Guangdong, 518055, China.
Lijie ChenChina Medical University, Shenyang, 110122, Liaoning, China.
Yibao FanDepartment of General Surgery and Integrated Chinese and Western Medicine, Institute of Precision Diagnosis and Treatment of Digestive System Tumors, Carson International Cancer Center, Shenzhen University General Hospital, Shenzhen University, Shenzhen, Guangdong, 518055, China.
Jinze ZhangDepartment of General Surgery and Integrated Chinese and Western Medicine, Institute of Precision Diagnosis and Treatment of Digestive System Tumors, Carson International Cancer Center, Shenzhen University General Hospital, Shenzhen University, Shenzhen, Guangdong, 518055, China.
Huan ChengDepartment of General Surgery and Integrated Chinese and Western Medicine, Institute of Precision Diagnosis and Treatment of Digestive System Tumors, Carson International Cancer Center, Shenzhen University General Hospital, Shenzhen University, Shenzhen, Guangdong, 518055, China.
Tingwei DengDepartment of General Surgery and Integrated Chinese and Western Medicine, Institute of Precision Diagnosis and Treatment of Digestive System Tumors, Carson International Cancer Center, Shenzhen University General Hospital, Shenzhen University, Shenzhen, Guangdong, 518055, China.
Lin YangDepartment of Hepatobiliary Surgery, Shaanxi Province, Xianyang Central Hospital, Xianyang, 712099, Shaanxi, China.
Weiwei WangDepartment of General Surgery and Integrated Chinese and Western Medicine, Institute of Precision Diagnosis and Treatment of Digestive System Tumors, Carson International Cancer Center, Shenzhen University General Hospital, Shenzhen University, Shenzhen, Guangdong, 518055, China.
Guoyong ChenDepartment of General Surgery and Integrated Chinese and Western Medicine, Institute of Precision Diagnosis and Treatment of Digestive System Tumors, Carson International Cancer Center, Shenzhen University General Hospital, Shenzhen University, Shenzhen, Guangdong, 518055, China. 13938238530@139.com.
Peiqin WangDepartment of Gastroenterology, Changzheng Hospital, Naval Medical University, Shanghai, 200003, China. fjqpq1987@163.com.
Peng GongDepartment of General Surgery and Integrated Chinese and Western Medicine, Institute of Precision Diagnosis and Treatment of Digestive System Tumors, Carson International Cancer Center, Shenzhen University General Hospital, Shenzhen University, Shenzhen, Guangdong, 518055, China. doctorgongpeng@szu.edu.cn.
Xing NiuDepartment of General Surgery and Integrated Chinese and Western Medicine, Institute of Precision Diagnosis and Treatment of Digestive System Tumors, Carson International Cancer Center, Shenzhen University General Hospital, Shenzhen University, Shenzhen, Guangdong, 518055, China. xniu@cmu.edu.cn.
Xianbin ZhangDepartment of General Surgery and Integrated Chinese and Western Medicine, Institute of Precision Diagnosis and Treatment of Digestive System Tumors, Carson International Cancer Center, Shenzhen University General Hospital, Shenzhen University, Shenzhen, Guangdong, 518055, China. zhangxianbin@hotmail.com.
Shenzhen University · CNZhengzhou University · CNAffiliated Hospital of Shaanxi University of Chinese Medicine · CNChanghai Hospital · CNChina Medical University · CNFirst Affiliated Hospital of Henan University of Science and Technology · CNIntegrated Chinese Medicine (China) · CNShanghai Changzheng Hospital · CNXian Yang Central Hospital · CN
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAccumulated evidence highlights the significance of the crosstalk between epigenetic and epitranscriptomic mechanisms, notably 5-methylcytosine (5mC) and N
methodsPan-cancer genomic analysis of the crosstalk between 5mC and m
results5mC and m
conclusionsOur findings suggest that HCC may result from a unique synergistic combination of 5mC-epigenetic mechanism mixed with m
Indexed as
Carcinoma, HepatocellularLiver Neoplasms5-MethylcytosineAdenosineApoptosisCell Line, TumorDisease ProgressionG2 Phase Cell Cycle CheckpointsHumansPharmacogenetics5-MethylcytosineAdenosineN-methyladenosine5-methylcytosineHepatocellular carcinomaMulti-omicsN6-methyladenosinePharmacogenomic landscapeTherapeutic response
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.